Bladder Cancer PIII Results in 2Q 2010 !! Bioniche
Seite 3 von 46 Neuester Beitrag: 25.04.21 03:05 | ||||
Eröffnet am: | 17.01.10 12:54 | von: Biotechmaste. | Anzahl Beiträge: | 2.126 |
Neuester Beitrag: | 25.04.21 03:05 | von: Ursularwlra | Leser gesamt: | 198.627 |
Forum: | Hot-Stocks | Leser heute: | 46 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 | 6 | 7 | 8 | 9 | ... 46 > |
ich schließe mich Biotechmaster an, jedoch habe ich ein kleines bisschen Bauchweh ob es wirklich so schnell geht.........
Nur meine persönliche Meinung keine KAUF- oder Verkaufsempfehlung
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
Es ist nur noch ein kurzer weg bis zum hoffentlich großen Knall ..
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
http://finance.yahoo.com/news/...oks-ibd-4281469438.html?x=0&.v=1
Endo Pharmaceuticals Looks For Acquisitions
On Friday August 27, 2010, 4:40 pm EDT
To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.
Having bought Penwest, Endo can now make all the decisions about Opana without consultation. It also won't need to pay Penwest the 22% in royalties that were part of the previous partnership deal.
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
Ich rieche förmlich den STURM NACH OBEN kann nicht mehr lange dauern .
Die 1,24-1,25$ muss fallen ....
wir brauchen z.Z. viele Nerven. Die Seitwertsbewegung ist überall. Es macht echt fast keine Lust mehr, weil sich jeder zurück zieht ins Schneckenhaus.
Also Nervennahrung tanken >> eine Mass << und wir werden ruhiger?!?!?!
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
http://ih.advfn.com/...=TSE:BNC&period=0&size=19&volume=1
Gute Nacht
echt zum kotzen. Zum Glück habe ich nur 2 Herzschmerzen im Depot und einige Schrittmacher die gut was bringen. Ich bin sehr überzeugt das es hier unabhängig des Marktes nach oben geht. Die Burger K. hat es ja bewiesen............
Das ist meine persönliche Meinung, keine Kauf- oder Verkaufsempfehlung
Eine schöne zusammenfassung
http://www.stockhouse.com/Bullboards/...&r=0&s=BNC&t=LIST
Schon zuvor haben sich einige positiv über Urocidin geäußert z.b. von diesem Verein für Blasenkrebs kranke die direkte kontakte zu Bioniche haben und von Alvaro Morales (der typ der das einzige bisher wirksame Medizin BCG für Blasenkrebs eingeführt hat) er ist auch bei Urocidin dabei .
Und zu guter letzt Urocidin hat alle DMC (Data monitoring) meetings positiv abgeschlossen zur gleichen Zeitpunkt hat Endo auch gleich die Weltweite Rechte an Urocidin übernommen .
Also für mich ist das ein eindeutiges Zeichen für sehr gute Phase 3 daten .
http://www.bladdercancersupport.org/...imit=6&limitstart=12#31862
I can tell you that the people I know at Bioniche are extremely positive about their product. 3 Months, 3 Weeks ago
------------------------------------
http://www.quintenews.com/2010/09/...r-year-for-bellevilles-bioniche/
TheCEO of Belleville’s Bioniche Life Sciences says after many yearsofworkand frustration the last fiscal-year was a “banner year”.GraemeMcRaesays the company signed an agreement with EndoPharmaceuticals,last year,to produce Urocidin….a bladder cancer drugand they areworking togethertoward production. He says work is alsocontinuing onthe faciity toproduce its animal e-coli vaccines.
He says shareholders will be really happy in two to three years whe nproduction of the bladder cancer drug starts to roll onto the market.
-----------------------------------
Dr. Alvaro Morales, professor of urology and oncologyat Queen’s University, Kingston, Ont., and principal investigator ofthe trial: “Myownexperiencesuggests very strongly that the safetyprofile of MCC ismuchbetter thanBCG and, certainly, MCC is easier tohandle, fromthepharmacist’s,nurse’s and physician’s points of view,duetothe risk ofacquiring a serious infection from improper handlingofBCG,which is alive bacteria, as opposed to MCC that containsonlybacterialcell wallfragments and DNA.” Dr. Morales is editor ofTheChronicle ofUrology &Sexual Medicine.
-----------------------------------------
http://www.medicalnewstoday.com/articles/161677.php
The Data Monitoring Committee (DMC) helditsninthmeeting regardingthis clinical trial last week. After itsmeeting,theCommittee hasrecommended that Bioniche "continue thetrialunmodifieduntil the nextscheduled or triggered meeting." The next scheduled meeting of theCommittee is scheduled to occur in October
Also noch ein weiteres gutes Zeichen mehr Vorzeichen geht nicht mehr .
Fiscal 2010 Year-End Results September 10,
The fully-integrated company employs 211 skilled personnel and has three operating divisions: Human Health, Animal Health, andFood Safety
Bioniche Reports Fiscal 2010 Second Quarter Results
10/02/10
The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, AnimalHealth, and Food Safety.
Current positions available:
We currently have the following positions available:
Biotechnologist
Belleville
Utilities Operator/Maintenance Technician
Belleville, ON
Canadian Sales Manager
Belleville, ON
Production Technologist (Bulk Antigen Production)
Belleville, ON
WER in die Rakete einsteigen will sollte nicht so lange zögern DENDREON läßt grüßen.
http://www.barchart.com/...p;submitted=1&fpage=&txtDate=#jump
Schaut euch die SUPER PII Ergebnisse an mit 128 Patienten in der aktuellen PIII sind es gerade mal 105 Patienten .
TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?
Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. [B]This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product.[/B] The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study